PMX-53

CAT: 0804-HY-106178-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-106178-01Size:5 mg
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
PMX-53 (3D53) is a synthetic peptidic and a potent and orally active complement C5a receptor (CD88) antagonist with an IC50 of 20 nM. PMX-53 is also a low-affinity MrgX2 agonist that stimulates MrgX2-mediated mast cell degranulation. PMX-53 specifically binds to C5aR1 and does not bind to the second C5aR (C5L2) and C3aR. PMX-53 has anti-inflammatory, anticancer and antiatherosclerotic effects[1][2][3][4][5][6].
CAS Number
[219639-75-5]
Product Name Alternative
3D53
UNSPSC
12352209
Target
Complement System
Type
Reference compound
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Inflammation/Immunology; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/pmx-53.html
Purity
99.85
Solubility
DMSO : 100 mg/mL (ultrasonic) |H2O : ≥ 50 mg/mL
Smiles
O=C(N[C@H](C(NCCC[C@@H]1NC([C@@H](NC(C)=O)CC2=CC=CC=C2)=O)=O)CCCNC(N)=N)[C@@H](NC([C@H](NC([C@@](CCC3)([H])N3C1=O)=O)CC4CCCCC4)=O)CC5=CNC6=CC=CC=C56
Molecular Formula
C47H65N11O7
Molecular Weight
896.09
References & Citations
[1]Subramanian H, et al. PMX-53 as a dual CD88 antagonist and an agonist for Mas-related gene 2 (MrgX2) in human mast cells. Mol Pharmacol. 2011 Jun;79 (6) :1005-13.|[2]Ting E, et al. Role of complement C5a in mechanical inflammatory hypernociception: potential use of C5a receptor antagonists to control inflammatory pain. Br J Pharmacol. 2008 Mar;153 (5) :1043-53.|[3]Holland MC, et al. Synthetic small-molecule complement inhibitors. Curr Opin Investig Drugs. 2004 Nov;5 (11) :1164-73.|[4]Finch AM, et al. Low-molecular-weight peptidic and cyclic antagonists of the receptor for the complement factor C5a. J Med Chem. 1999 Jun 3;42 (11) :1965-74.|[5]Manthey HD, et al. Complement C5a inhibition reduces atherosclerosis in ApoE-/- mice. FASEB J. 2011 Jul;25 (7) :2447-55.|[6]Vadrevu SK, et al. Complement c5a receptor facilitates cancer metastasis by altering T-cell responses in the metastatic niche. Cancer Res. 2014 Jul 1;74 (13) :3454-65.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, sealed storage, away from moisture and light, under nitrogen)
Scientific Category
Reference compound1
Clinical Information
Phase 2

Related Products

CatalogName
HY-110136-01PMX 205
HY-110136A-01PMX 205 (Trifluoroacetate)
HY-168119HPK1-IN-53
HY-149208-01HDAC-IN-53
HY-P10982SjDX5-53
HY-162992NLRP3-IN-53
HY-178028PRMT5-IN-53
HY-177378HBV-IN-53
HY-175512Tubulin-IN-53
HY-149729ICMT-IN-53

Alternative Products

CatalogName
256289PMX 53
T28429PMX-53
A22479-5PMX-53 5mg
A22479-25PMX-53 25mg
T83669-01PMX-53 TFA
A22479-1PMX-53 1mg
A22479-50PMX-53 50mg
A22479-10PMX-53 10mg
CRB1000989-01PMX 53 - (Immunology - Antigens/Epitotes/Pools/Librairies)
BUP09044-01PMX 53 acetate (219639-75-5 free base)

Popular Products